United Therapeutics (NASDAQ:UTHR) CEO Sells $5,090,195.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $535.81, for a total value of $5,090,195.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,707,270.53. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Price Performance

UTHR opened at $588.36 on Tuesday. The firm has a market cap of $25.79 billion, a PE ratio of 21.09, a P/E/G ratio of 1.88 and a beta of 0.84. The stock has a 50-day moving average price of $498.42 and a 200-day moving average price of $474.96. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $607.89.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million for the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the prior year, the firm posted $6.19 EPS. As a group, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: TETON‑1 (Tyvaso) pivotal success — the 598‑patient Phase 3 trial met its primary endpoint, showing a Hodges‑Lehmann estimate of +130.1 mL change in absolute FVC at week 52 vs. placebo, a clinically meaningful result that expands Tyvaso’s potential market beyond PAH. Read More.
• Positive Sentiment: Ralinepag Phase 3 readout + buyback momentum — investors are still digesting positive ADVANCE OUTCOMES ralinepag data (large reduction in clinical‑worsening risk) and United Therapeutics’ board authorized up to $2B in buybacks with ~$1.5B in ASRs, which accelerates share‑count reduction and supports EPS. Read More.
• Positive Sentiment: Surge in call‑option activity — unusually large options flow (≈16,800 calls, ~789% above normal) signals bullish positioning and likely amplified intraday upside through speculative buying and short‑covering. (Market data entry)
• Positive Sentiment: Analyst lift — TD Cowen raised its price target to $660 and reiterated a Buy view, which likely reinforced investor conviction after the clinical news. Read More.
• Neutral Sentiment: Read‑through to peers — some smaller respiratory/rare‑disease names saw moves on trial read‑throughs and analyst notes (e.g., Insmed), but the competitive or regulatory implications for other firms remain speculative. Read More.
• Negative Sentiment: Insider selling — CEO Martine Rothblatt sold 9,500 shares on March 26, and public filings show extensive insider sales over recent months; while not unusual for a high‑value stock, heavy insider disposals can be perceived as a headwind by some investors. Read More.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently made changes to their positions in the company. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $26,000. Activest Wealth Management boosted its holdings in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB increased its holdings in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in United Therapeutics during the fourth quarter valued at approximately $48,000. 94.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on UTHR shares. Oppenheimer raised their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. UBS Group upped their price objective on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Finally, TD Cowen boosted their price target on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $557.64.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.